Abstract-The influence of blood pressure on outcomes after high-risk myocardial infarction is not well characterized. We studied the relationship between blood pressure and the risk of cardiovascular events in 14 703 patients with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction in the Valsartan in Myocardial Infarction Trial. We assessed the relationship between antecedent hypertension and outcomes and the association between elevated (systolic: Ͼ140 mm Hg) or low blood pressure (systolic: Ͻ100 mm Hg) in 2 of 3 follow-up visits during the first 6 months and subsequent cardiovascular events over a median 24. 
H ypertension is an established risk factor for progression of cardiovascular disease, 1 and antihypertensive treatment has been associated with reduced risk of myocardial infarction (MI), heart failure (HF), stroke, and cardiovascular death. 2, 3 While hypertension before MI is associated with greater left ventricular (LV) dilation 4, 5 and a higher risk of subsequent HF, stroke, and death, 6 -12 a drop in blood pressure after MI is common. 13, 14 Thus, the influence of post-MI blood pressure on cardiovascular outcomes may be complex, particularly in patients with large infarctions. To better understand the relationship between blood pressure and risk in the post-MI patient, we performed a posthoc analysis of data from the VALsartan In Acute myocardial INfarction Trial (VALIANT) to assess the effect of antecedent hypertension and post-MI systolic blood pressure on subsequent adverse cardiovascular outcomes.
Methods

Patients
VALIANT enrolled 14 703 patients with LV dysfunction (LV ejection fraction: Ͻ35%), HF, or both who had systolic blood pressure Ͼ100 mm Hg between 12 hours and 10 days after an acute MI. Patients were randomly assigned to receive valsartan (160 mg twice daily), captopril (50 mg 3 times a day), or both (80 mg of valsartan twice daily and 50 mg of captopril 3 times a day). 15, 16 All of the patients gave written informed consent, and the research protocol was approved by the appropriate institutional review boards.
Assessment of Hypertension and Follow-Up Blood Pressure
Information on antecedent hypertension and other baseline data were assessed at the randomization visit. Patients who reported a diagnosis of hypertension before randomization were considered to have hypertension antecedent to their MI. Blood pressure was recorded at each follow-up visit, with the second visit on discharge or day 14, whichever came first, and subsequent visits scheduled at 1, 3, 6, 9, and 12 months after randomization and every 4 months thereafter. Because blood pressure was assessed primarily for safety, no recommendations for blood pressure measuring or number of times to measure blood pressures at each visit were provided, although if Ͼ1 blood pressure result was measured, investigators were asked to report the lowest. No specific instructions were given to investigators on how to treat blood pressure.
Patients who completed Ն2 visits after discharge and 1 visit between 4 and 8 months and were free of clinical events were considered for the analyses as 6-month event-free survivors. Patients with a systolic blood pressure Ͼ140 mm Hg on 2 of the visits at 1, 3, and 6 months were considered to have an elevated blood pressure. Patients with a systolic blood pressure Ͻ100 mm Hg on 2 of the visits at 1, 3, and 6 months were considered to have low blood pressure. The remaining patients were considered to have normal blood pressure. The same cutoffs were used for all of the patients irrespective of comorbidities, such as diabetes or renal impairment.
Statistical Analysis
All of the major cardiovascular end points, including death, MI, stroke, resuscitated cardiac arrest, and hospitalization for HF, were adjudicated by an independent clinical events committee, and deaths In addition, analyses of the association between post-MI blood pressure and outcomes were adjusted for antecedent hypertension, and we assessed for statistical interaction. Supportive analyses of the nature of the relationship between the average systolic blood pressure across the 1-, 3-, and 6-month visits as a continuous variable and subsequent outcomes were performed by allowing for increasingly complex relationships (linear, quadratic, cubic, and splined) and reporting the simplest relationship that significantly improved model fit compared with the preceding one, adjusting for baseline covariates. To further test the robustness of our analyses, we performed a Cox analysis with high or low systolic blood pressure as a time-dependent variable censored 30 days before first event.
Results
Antecedent Hypertension
At the time of enrollment, 8575 patients (58.3%) reported antecedent hypertension, and 7609 (88.7%) of these reported receiving medical treatment for hypertension (no information on 2 patients). Patients with antecedent hypertension were older, more often female, had higher blood pressure at baseline, higher BMI, lower eGFR, lower peak creatinine kinase, higher prevalence of previous cardiac disease and risk factors, and were more likely to receive antihypertensive medication (Table 1) . Patients with antecedent hypertension had higher average systolic blood pressures across the follow-up visits at 1, 3, and 6 months compared with patients who did not report antecedent hypertension (difference in medians: 9 mm Hg; PϽ0.0001). Antecedent hypertension was associated with a statistically significant increased risk of stroke, HF hospitalization, cardiovascular death, and a combined cardiovascular outcome of cardiovascular death, MI, HF hospitalization, stroke, or sudden death or resuscitated cardiac arrest in multivariable analyses (Table 2) . Antecedent hypertension did not affect the risk of developing renal impairment (Pϭ0.3) or hyperkaliemia (Pϭ0.4).
Post-MI Blood Pressure
Of the 10 532 patients who had not experienced a cardiovascular event by the 6-month follow-up visit and had adequate follow-up information, 1522 (14.5%) had elevated systolic blood pressure, and 602 (5.7%) had low blood pressure 1 to 6 months post-MI. Patients with elevated systolic blood pressure post-MI were older, more often female, had lower eGFR, lower peak creatinine kinase, and had a higher prevalence of cardiovascular risk factors and previous HF (Table 3) . Patients with elevated systolic blood pressure were more likely to receive the target dose of the study drug compared with patients with normal systolic blood pressure. Compared with patients with normal systolic blood pressure, patients with elevated systolic blood pressure were at significantly higher risk of stroke and a combined cardiovascular outcome of cardiovascular death, MI, HF hospitalization, stroke, or sudden death or resuscitated cardiac arrest (Table  4) . Adding information about LV ejection fraction to the model (nϭ8220) did not substantially change these results. Elevated systolic blood pressure was most associated with the adverse cardiovascular outcome in patients who received a statin (P for interactionϭ0.0001) and in patients not using long-lasting nitrates (P for interactionϭ0.001).
Patients with low systolic blood pressure between 1 and 6 months after MI were at a higher risk of HF, cardiovascular death, all-cause death, and the combined cardiovascular outcome. Patients with low systolic blood pressure were more likely to experience renal impairment (adjusted hazard ratio [HR]: 1.43; 95% CI: 1.01 to 2.04; Pϭ0.047). Adding information about LV ejection fraction to the model attenuated the 
2).
Assessing the relationship between the average systolic blood pressure across the 1-, 3-, and 6-month visits as a continuous variable and the risk of subsequent cardiovascular events demonstrated a linear relationship between increasing systolic blood pressure and stroke (P for linear termϭ0.003) and a quadratic relationship between systolic blood pressure and the risk of all-cause death (P for quadratic termϭ0.0003; nadir: 135 mm Hg), cardiovascular death (Pϭ0.002; nadir: 135 mm Hg), sudden death or resuscitated cardiac arrest (Pϭ0.02; nadir: 127 mm Hg), and combined cardiovascular events (Pϭ0.004; nadir: 131 mm Hg; Figure) . The average systolic blood pressure across the 1-, 3-, and 6-month visits was not associated with the risk of recurrent MI (P for linear, quadratic, cubic, or splined, all Ͼ0.2), whereas the relationship with the risk of hospitalization for HF was complex (P for cubic fitϭ0.002). A time-dependent Cox analysis also demonstrated that both post-MI systolic blood pressure Ͼ140 mm Hg (adjusted HR: 1.11; 95% CI: 1.01 to 1.21; Pϭ0.03) and systolic blood pressure Ͻ100 mm Hg (adjusted HR: 1.38; 95% CI: 1.21 to 1.59; PϽ0.0001) were significantly associated with the combined outcome. Classification of patients based on diastolic blood pressure demonstrated trends similar to those seen for systolic blood pressure, but the relationships were not significant because of the lower number of patients with consistent diastolic blood pressure Ͻ60 mm Hg (nϭ301) or Ͼ90 mm Hg (nϭ302).
Discussion
We observed that antecedent hypertension at the time of MI is strongly associated with adverse cardiovascular outcomes in patients with LV dysfunction, HF, or both receiving contemporary therapy, including inhibitors of the renin-an- BP indicates blood pressure; CV, cardiovascular; HF, hospitalization for heart failure. *Adjusted for age, sex, BMI, eGFR, previous MI, previous HF, previous stroke, baseline diabetes, peripheral vascular disease, history of hypertension, and NYHA class at 6 months. 
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Pre-MI and Post-MI Hypertension and Outcomes 5 giotensin system. Moreover, in this well-treated cohort, in which nearly all of the patients, by design, received an renin-angiotensin system inhibitor, 68% received a ␤-blocker, and 84% received Ն1 antihypertensive drug in addition to study drug; Ϸ15% of post-MI patients who survived to 6 months had elevated systolic blood pressure on 2 of 3 visits, and these patients were at increased risk for subsequent stroke and combined cardiovascular events compared with patients with normal blood pressure. The effect of hypertension on the risk of adverse CV events has been well documented in patients without MI, 17 and our results confirm previous findings that antecedent hypertension increases the risk of HF, stroke, and death after MI. 6 -8,18 -21 Other studies have also examined the relationship between post-MI blood pressure and outcomes. A U-shaped relationship between diastolic blood pressure and death from coronary heart disease was observed in patients with a previous MI from the Framingham Heart Study cohort, 22 whereas a linear increase in the risk of reinfarction and coronary heart disease death was seen with increasing systolic blood pressure. 23 However, an analysis of the Coronary Drug Project found no relation between diastolic or systolic blood pressure after MI and adverse cardiovascular outcomes when adjusting for other clinical variables. 24 Low diastolic or systolic blood pressure was associated with adverse outcome early after MI in the Multiple Risk Factor Intervention Trial, whereas high blood pressure was worse for long-term outcome. 11 In 2677 community-based post-MI patients, the risk of stroke was increased with higher diastolic and systolic blood pressure after MI, whereas reinfarction and all-cause death were associated with low diastolic blood pressure only. 25 Finally, the International Verapamil-Trandolapril Study, in which a third of the patients had a previous MI, and Ϸ5% had HF, noted a quadratic relationship between blood pressure and the rate of death, MI, or stroke. 26 Although decreased blood pressure after MI may be associated with reduced LV function, and our data demonstrate higher morbidity and mortality in patients with low blood pressure after MI, we and others have found that elevated blood pressure in medium-and long-term survivors of MI re-emerges as a potent risk factor for new cardiovascular events. Although a number of mechanisms may underlie the increased risk associated with post-MI hypertension, we have shown previously that patients with a previous history of hypertension are at the greatest risk for adverse LV remodeling post-MI, which itself is associated with an increased likelihood of adverse outcomes. 4 Similarly, LV hypertrophy, a consequence of hypertension, is itself an independent predictor of both adverse remodeling and clinical outcomes post-MI. 5, 9 Unfortunately, few data on patients with high-risk MI are available from the large, randomized, placebocontrolled hypertension trials, which either specifically excluded patients with HF or included too few patients with a previous MI to perform adequate subgroup analyses. [27] [28] [29] [30] Thus, whether aggressive blood pressure treatment in the post-MI population would reduce the risk of stroke or other cardiovascular events remains unknown.
Our finding that elevated blood pressure at follow-up was associated with adverse cardiovascular outcome in high-risk, post-MI patients contrasts with large studies of patients with acute or stable HF. In these studies, increasing blood pressure has generally been associated with improved prognosis, even for patients with blood pressure in the normal and high range. [31] [32] [33] [34] [35] This finding may be explained in part by the fact that 44% of the patients in VALIANT were in NYHA class 1 at the 6-month follow-up visit, and only 11% were in class 3 or 4. Thus, whereas cardiac function may be the main determinant of outcome in the HF population, in post-MI patients without overt HF, elevated blood pressure may be more common and may reflect an increased risk of ischemic events.
Some important limitations of this analysis should be noted. Patients who survived to the 6-month follow-up visit were not representative of the baseline cohort, and these differences may reflect significant survivor bias, potentially limiting the generalizability of our findings to early post-MI patients. We cannot exclude the possibility that some patients not considered hypertensive at 6 months might have lower blood pressure secondary to worsening LV function. The interpretation of the effect of diastolic blood pressure on outcomes is complicated by the potential for increased pulse pressure because of increased conduit vessel stiffness. Finally, because VALIANT was not a hypertension trial, there was no strict definition of antecedent hypertension, and blood pressure was measured during the trial in an ambulatory setting with no strict protocol. Nevertheless, this limitation likely attenuated the true relationship between post-MI hypertension and outcome.
Perspectives
Both low and elevated systolic blood pressure after a highrisk MI are associated with an increased risk for adverse cardiovascular events. Elevated systolic blood pressure, a potentially modifiable risk factor, is associated with a profound increase in the risk of stroke. Whether more aggressive treatment of elevated blood pressure in patients with a previous MI can reduce adverse outcomes remains unknown.
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